4 completed, 1 terminated, 1 unknown. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Human Papillomavirus: new trials by email Literature Review of Human Papillomavirus trials Research Report on Human Papillomavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions Aldesleukin, E6 T Cell Receptor (TCR) - Human Papillomavirus, HPV-16 | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2018-01-09 | 2021-02-16 |
| Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers GX-I7, Placebo - Human Papillomavirus | Phase 1 | Completed | Genexine, Inc. | 32 | 2017-02-16 | 2018-10-23 |
| A Phase I Clinical Trial of an HPV Therapeutic Vaccine Vaccine consisting of four HPV-16 E6 peptides in combination with CandinĀ® - Human Papillomavirus | Phase 1 | Completed | University of Arkansas | 52 | 2012-08-01 | 2016-10-12 |
| Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females HPV 16/18 vaccine, 0,5ml, Placebo control, 0.5ml, HPV 16/18 vaccine, 1.0ml - Human Papillomavirus | Phase 1 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 160 | 2012-02-01 | 2012-03-08 |
| The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru Gardasil - Cervical Intraepithelial Neoplasia, Cervical Cancer | Phase 1 | Completed | Preventive Oncology International, Inc. | 642 | 2011-05-01 | 2014-04-21 |
Uterine Cervical Neoplasms (3) · Anus Neoplasms (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Oropharyngeal Neoplasms (1) · Penile Neoplasms (1) · Squamous Intraepithelial Lesions (1) · Uterine Cervical Dysplasia (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Neoplasms (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Uterine Cervical Diseases (3) · Uterine Diseases (3) · Uterine Neoplasms (3) · Anus Diseases (1) · Colonic Diseases (1) · Colorectal Neoplasms (1)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Interleukin-2 (1) · aldesleukin (1) · bintrafusp alfa protein, human (1) · efineptakin alfa (1) · entinostat (1)
National Cancer Institute (NCI) (2) · Genexine, Inc. (1) · Preventive Oncology International, Inc. (1) · Shanghai Zerun Biotechnology Co.,Ltd (1) · University of Arkansas (1)
United States (3) · China (1) · Peru (1) · South Korea (1)
Carlos Vallejos Sologuren, MD (1) · Hoyoung M Maeng, M.D. (1) · Jae Kwan Lee, MD, PhD (1) · Jerome L Belinson, MD (1) · Mayumi Nakagawa, MD, PhD (1) · Scott Norberg, DO (1) · William W Greenfield, MD (1) · Yan-ping Li, MD (1)
R01CA143130 (1)